Nevertheless, although this emerging preliminary data is of interest, until more definitive information regarding the association between mutation status and treatment outcomes, as well as the optimal predictive biomarker panel becomes available, MEK inhibitors should be considered as an option for all women with recurrent low-grade serous carcinoma, regardless of mutation status. Here, MAP2K7 is linked to serous adenocarcinoma.